Search Results for: California Stem Cell Treatment Center

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up?

/ / 3 Comments
Burst Biologics, Christopher Jones

The New York Times just broke a story on Burst Biologics and Weill Cornell that fits with long-standing troubling questions about regenerative biologics producers. The story also bears on the doctors and hospitals like Weill Cornell that were or are customers of the suppliers. Further, what is the FDA’s role in all of this? The […]

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up? Read More »

3rd Invitrx warning highlights FDA oversight weakness

/ / 8 Comments

The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past

3rd Invitrx warning highlights FDA oversight weakness Read More »

Weekly reads: $1B Saudi anti-aging push, OCT4 necklace, cancer trial wows, coffee brain

/ / 1 Comment
Stem-Cells-Aging, anti-aging

I recently wrote about stem cell-related ideas for anti-aging and even cheating death, but there are of course other approaches including drugs like metformin. A new article outlines a massive research funding plan to tackle aging. Let’s start with that. Recommend reads including anti-aging Saudi Arabia plans to spend $1 billion a year discovering treatments to

Weekly reads: $1B Saudi anti-aging push, OCT4 necklace, cancer trial wows, coffee brain Read More »

FDA news: warning letter pattern, cancer moonshot, CAR-T & gene-editing guidance

/ / Leave a Comment
FDA

The FDA has been busy with the COVID pandemic but it has many other things on its plate as well including cell therapies. Today I’m sharing some recent agency news and brief perspectives on it. FDA focus on clinic-related umbilical cord cell drug makers The agency warned an Idaho company that produces and sells umbilical

FDA news: warning letter pattern, cancer moonshot, CAR-T & gene-editing guidance Read More »

Weekly reads: CTCF, Sox transcription factors, Clinic fires back, more

/ / 2 Comments
heart stem cells

I’m taking a short break today from working on a big grant to put out this weekly reads post including on Sox transcription factors, cord blood paper controversy, and other interesting papers such as one on CTCF and chromatin domains after mitosis that really struck me. I can actually see blue sky today here in

Weekly reads: CTCF, Sox transcription factors, Clinic fires back, more Read More »

Weekly reads: Alzheimer’s, dinosaur brains, teratoma, vampire amoeba, new H3K27me3 reader

/ / 1 Comment
vampire-amoeba-sm

Anyone with a seemingly only semi-functional nervous system now post-election might be turning to science to help their brains bounce back. Here are some of the things I’ve been reading or hope to soon. In good news for the stem cell and regenerative medicine field, especially here in California, it looks like us California voters

Weekly reads: Alzheimer’s, dinosaur brains, teratoma, vampire amoeba, new H3K27me3 reader Read More »

Weekly reads: ‘junk DNA’, COVID chaos, CRISPR CasΦ, & postdoc opps, more

/ / 2 Comments
Retroviral-genes-Junk-DNA-NIHsmall

Here are our weekly recommended regenerative medicine and other notable science reads including a few things on COVID. It’s been quite an interesting week. “Junk DNA” is not so junky, role in differentiation NIH scientists showed how ancient retroviral genes, or “junk DNA”, may play a role in helping stem cells decide to become neurons. This

Weekly reads: ‘junk DNA’, COVID chaos, CRISPR CasΦ, & postdoc opps, more Read More »